بدائل البحث:
significantly mediate » significantly mediated (توسيع البحث), significantly predicted (توسيع البحث), significantly mitigated (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
mediate decrease » mean decrease (توسيع البحث), mediated defense (توسيع البحث)
يعرض 381 - 400 نتائج من 1,931 نتيجة بحث عن '(( significant decrease decrease ) OR ( significantly mediate decrease ))~', وقت الاستعلام: 0.21s تنقيح النتائج
  1. 381
    Calcitriol suppresses proliferation of CaSki cells.

    Calcitriol suppresses proliferation of CaSki cells. حسب Euclides Avila (41023)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:
  2. 382
    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:
  3. 383
    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:
  4. 384
    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:
  5. 385
    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay حسب Di Han (618795)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:
  6. 386
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  7. 387
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  8. 388
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  9. 389
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  10. 390
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  11. 391
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  12. 392
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  13. 393
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
    أضف إلى المفضلة
    محفوظ في:
  14. 394
    A proposed model for citrus tristeza virus (CTV) p20-mediated RNA silencing suppression.

    A proposed model for citrus tristeza virus (CTV) p20-mediated RNA silencing suppression. حسب Yongle Zhang (11355546)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  15. 395
    CTV p20 interacts with NbSGS3 and mediates autophagic degradation of NbSGS3.

    CTV p20 interacts with NbSGS3 and mediates autophagic degradation of NbSGS3. حسب Yongle Zhang (11355546)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  16. 396
    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold change (2<sup>-ΔΔCt</sup>). miRNAs with a fold change greater than 1.3 in the vehicle group and at the 0.75–1.3 range (orange striped area) in the Bz and Bz + PTX therapy groups were considered to have a restored expression. They were selected for further analysis on IPA software. (A) The expression of miRNAs was altered in the infected group and an expression was restored after Bz therapy. (B) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (C) Diseases and disorders pathway analysis. (D) The expression of miRNAs was altered in the infected group and restored upon Bz + PTX therapy. (E) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (F) Diseases and disorders pathway analysis. Significant intervals

    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold chang... حسب Glaucia Vilar-Pereira (686134)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  17. 397
    Schematic illustration of the proposed role of XO and NOX4 in the heart of PG-LPS-treated mice.

    Schematic illustration of the proposed role of XO and NOX4 in the heart of PG-LPS-treated mice. حسب Akinaka Morii (12709672)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  18. 398
    The original plotting data.

    The original plotting data. حسب Hongmei Qian (538647)

    منشور في 2024
    "…</p><p>Results</p><p>In glaucomatous mice, RTA408 significantly reduces the apoptosis levels of RGCs and decreases RGC loss. …"
    أضف إلى المفضلة
    محفوظ في:
  19. 399
    S1 Raw data -

    S1 Raw data - حسب Muhammad Naeem Sattar (19828497)

    منشور في 2024
    "…The larval duration was also decreased significantly in the larvae treated with all the dsRNA treatments. …"
    أضف إلى المفضلة
    محفوظ في:
  20. 400
    Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase.

    Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase. حسب Elsie D. Oduor (22521785)

    منشور في 2025
    الموضوعات:
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: